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I PI1 56 I In vitro Activity of BAY 12-8039 
D. F e h g h a m ' ,  M.J. Robbins', A. Leakey', H. Salman', 
C. Dencer', S. Clark', G.L. Ridgway', R.N. Griineberg'. 'GR 
Micro Lid, London, UK, UCLH N H S  Trust, London, UK 
The in vim activity of BAY 12-8039 (l-cyclopropyl-7 [(S,S)-2,8 
diazabicyclo [4.3.0] non-8-yl]-6-fluoro-8-methoxy-l, 4-dihy- 
dro-4-oxo-3-quinoline carboxylic acid), a new fluoroquinolone, was 
determined against a wide range of clinical bacterial isolates and 
compared with that of ofloxacin. BAY 12-8039 was highly ac- 
tive against all Gram positive species tested being genedy 4-8 
times more active than ofloxacin against fluoroquinolone-susceptible 
(MIC ofloxacin 5 2  mg/L) isolates (MICw [mg/L] Staphylococcus spp. 
0.12, S. pneumoniae 0.12, E.faecalis 0.25 mg/L). BAY 12-8039 was 
also hghly active against isolates of H .  injuenzae (MICw 0.06), M .  
catarrhalis (MIC90 0.12), Neisseria spp. (MIC90 0.03), Legionelh spp. 
(MIC90 0.015), ofloxacin-susceptible isolates of the Enterobacteri- 
aceae (MICso range 0.03-0.5), Campylobacter spp (MIC90 0.5) and 
Mbrio spp. (MIC90 0.25). BAY 12-8039 was somewhat less active 
against isolates of Ps. aemginosa (MIC90 2). BAY 12-8039 was very 
active against M .  pneumoniue (MIC90 0.12), M. hominis (MICgo 0.06), 
U urealyticum (MIC90 0.06), C. trachomatis (MIC90 0.12), C. pneumo- 
niae (MIC90 0.12) and M .  tuberculosis (MIC90 0.25). BAY 12-8039 
was also active against obligate anaerobes including B. jagilis, Pre- 
votella melaninogenica and Fusobacten'um spp. (all 1) and against 
Peptostreptococcus spp. (MIC90 0.25). C. pe&ngens (MIC90 0.5) and 
C. d&le (MICw 1). These results demonstrate the broad spectrum 
antibacterial potency of BAY 12-8039 whlch includes, in particu- 
lar, Gram positive bacteria and a wide range of pathogens of the 
respiratory tract. 
I PI157 I Susceptibility of Anaerobic Bacteria to BAY 
12-8039, a New Fluoroquinolone 
C.E. Nord, C. Edlund. Huddinge University Hospital, Karolinska 
Institute, Stockholm, Sweden 
Objectives: The aim of the present investigation was to determine 
the in vitro activity of BAY 12-8039 compared with other antimi- 
crobial agents against anaerobic bacteria. 
Methods: The activity of BAY 12-8039 was determined against 
360 c h c a l  isolates of anaerobic bacteria by the agar dllution 
method and were compared with levofloxacin, mvafloxack, ce- 
foxitin, imipenem, dindamycin and memnidazole. 
Results: BAY 12-8039 and imipenem were the most ac- 
tive agents tested. Anaerobic cocci (50 strains) had the follow- 
ing minimum inhibitory concentrations: BAY 12-8039, range 
0.125-1.0 mg/l; imipenem, range 0.016-0.064 mg/l. Propionibac- 
terium acne5 (30 strains): BAY 12-8039, 0.064-0.5 mg/l; imipenem, 
0.032-0.064 mg/l. Clostridium perfringens (30 strains): BAY 12-8039, 
0.25-1.0 mg/l; imipenem, 0.0164.5 mgA. Clostridium d@le (50 
stra ins) :  BAY 12-8039, 1.0-2.0 mgA; imipenem, 4.0-8.0 mgA. 
Buteroides jagilis (50 strains): BAY 12-8039, 0.125-1.0 mg/l; 
imipenem, 0.064-0.25 mgA. Bacteroides, Potphyromonas and Prwotella 
species (100 strains): BAY 12-8039, 0.1254.25 mgfl; imipenem, 
0.0164.25 mg/l. Fusobacteria (50 strains): BAY 12-8039, 0.25-1.0 
mg/l; imipenem, 0.008-0.064 mgA. 
Conclusions: BAY 12-8039 may be useful as treatment and pro- 
phylaxis for infections due to anaerobic bacteria. 
Macrolides, streptogramins and 
miscellaneous antibiotics 
m/ In-Viio Pharmacodynamic Parameters 
Describing Efficacy of Quinupristin/Dalfopnstin 
Against Multiple Bacterial Pathogens 
0. Vesga, W.A. Craig. VA Hospital and Uniwsity of Wisconsin, 
Madison, W, USA 
The neumpenic mouse thigh-infection model was used to de- 
termine the pharmacokinetic/pharmacodynamic (PWPD) param- 
eter best describing antimicrobial activity of the new streptogramin 
RP59500 (RP). RP is a combination of two semi-synthetic pristi- 
namycin derivatives, quinupristin (Q) and dalfopristin @), which 
displays strong synergistic effect agaimt gram-positive organisms, in- 
cluding those resistant to known antibiotics. Finding the PK/PD 
parameters predicting efficacy is important because Q, D, and RP 
MICs exhibit wide variation and do not reflect in-vivo response. 
Mice were infected with 4 strains of methich-susceptible (2 
MSSA) and -resistant (2 MRSA) S. aureu and 11 s t r a i n s  of peni- 
cillin-susceptible (1 PSSP), -intermediate (4 PISP), and -resistant 
(6 PRSP) S. pneumoniae. Both MRSA, 3 PISP and 4 PRSP were 
erythromycin-resistant. Mice had 7.04 f 0.65 loglo CFU/Thigh 
when treated for 24 h with RP 2.5-1280 mg/Kg divided into 2 or 
4 doses. A sigmoid dose-response model was used to estimate, by 
non-linear regression, the dose required to produce a net bacterio- 
static effect over 24 h (static dose) and the correlation of PWPD 
parameters with in vivo efficacy of RP. Stepwise regression analy- 
sis was used to estimate the PWPD parameter best predicting static 
dose of RP. Q MIC, but not D MIC or RF' MIC, predicted static 
dose of R P  (R' = 91, 0.4, and 20%, respectively). Of all parameters, 
RP AUC/MIC + Q AUC/MIC exhibited the greatest correlation 
with eficacy (Rz = 67%). Q, D, and RP AUC/MIC ratios, alone 
(Rz = 43. 30, and 62%, respectively) or in any other combination, 
do not reflect the eficacy of RP as well as the addition of FU' + Q 
ratios. 
F1 Antipneurnococcal Activity of RP59500 
(Quinupnstin/Dalfopnstin) as Determined by 
MIC and Time-Kill-Curves 
R.R. Reinert ', S. Simic ', M. Kresken ', R. Liimcken '. 'Institute 
of Medical MicrobioloB, University Hospital of Aachen, Germany, 
'RhBne-Poulenc Rorer, Cologne, Germany 
Objectives: Determination of the antipneumococcal activity of 
the first injectable streptogramin combination -59500 (quin- 
upristin/dalfopristin) by MIC and time-kill-curves. 
Methods: The in vim activity of RP59500 against a group of 93 
pneumococcal isolates fiom systemic infections was determined by 
the standard agar dution method according to the recommendations 
of the National Committee of Clinical Laboratory Standards. 
Results: Of the isolates, 32 were penich-sensitive (Pen-S) and 
erythromycin (Ery-S), 30 erythromycin-resistant (Ery-R) and Pen-S, 
and 31 were penicillin-intermediate (Pen-I) and Ery-S. Against the 
first group of strains (Pen-S, Ery-S) RP59500 showed good ac- 
tivity (MIC90 = 0.5 mg/L). Similar results were obtained for the 
Pen-I Ery-S p u p  of the strains (MIC90 = 0.5 mg/l). Ery-R 
s t r a i n s  were slightly less susceptible (MIC90 = 1 mg/l). Time kill 
testing of 3 Ery-S ckndamycin-susceptible (Ch-S), 3 Ery-R clin- 
damycin-resistant, and 3 Ery-R Ch-S  strains were performed at 0, 
1, 2, and 4 h. RP59500 yielded rapid Iallmg. 
Conclusions: In view of the good activity against all pneumo- 
cocci tested, including Pen-I and Ery-R isolates, -59500 might 
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be useful in the treatment of pneumococcal infections and warrants 
therefore further investigation. 
I PI1 60 1 In Vtro Activity of QuinupristinIDaIfopristin 
(RP 59500) against Enterncoccus faecium 
a! Witte', I. Klare', M. Kresken'. 'Robert Koch Institute, 
Wernigerode, Germany, 'Paul-Ehriich-Society for Chemotherapy, Study 
Group 'Bacterial Resistance', Cologne, Germany 
Objectives: To evaluate the in vim activity of RP 59500, a combi- 
nation of the two semisynthetic streptogramins (quinupristin/dalfo- 
pristin) against 150 clinical isolates of Enterocowfaecium. 
Methods: 72 strains being resistant to glycopeptides (VRE) were 
sent from 21 German hospitals to the Robert Koch Institute for epi- 
demiological investigations. The other 78 strains (including 3 VRE) 
came from a collaborative study conducted by the Study Group 
'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemother- 
apy (comprising 32 centres in Austria, Germany and Switzerland) in 
November 1995. MICs and MBCs were determined by the broth 
microdilution method. 
Red* MICs for the 78 st ra ins  of the collaborative s t u d y  
were as follows: 50.5 mg/15, 1 mg/124, 2 mg/132, 4 mg/l:12, 
8 mgA4, and 16 mg/ll.  The 72 VRE sent to the RKI e h b -  
ited Merent Smalmamrestriction patterns and were of the vanA 
genotype as evidenced by PCR. 6 of these strains also exhibited 
macrolide-hcosamide-streptogramin B resistance (demonstration of 
ermB gene by PCR). MICs for quinupristin/dalfopristin were as 
follows 50.5 mgk15, 1 mg/112, 2 mg/l:30, 4 mgA12, and 32 
mgk3. MICs of strains containing ermB were in the same range as 
ermB negative serains. MBCs were (2 mg/l for 6 strains, 32 mg/l 
for 8 strains, and z64  mg/l for 58. 
Conclusions: In vim, quinupristin/dalfopristin is active against 
E. faecium including VRE, but had no or weak bactericidal activity 
against most strains. 
I PI161 I Susceptibility of Staphylococci Growing on 
Fibronectin-Coated Catheter Surfaces to RP 
59500 (Quinupristin/DaIfopristin) 
U. Frank, M. Schumacher, ED. Daschner. Insfituteefor Environmental 
Medicine, Hospital Epidemiology, University Hospital, Freiburg, Germany 
Objectives: To study the activity of RP 59500, a mixture of two 
semisynthetic streptogramin antibiotics (quinupristin/dalfopristin), 
in an in vitro model of staphylococcal catheter-related mfection. 
Methods: Polyurethane catheter segments (length: 12 cm) were 
coated with a monolayer of fibronectin (300 ng/cm2) and then in- 
cubated for 72 h at 37°C with a 1-ml suspension containing lo6 
cfu/ml S. aureus ATCC 29213 or S. epidermidis K H  6 in sterile nor- 
male saline. Following incubation, catheters were treated with RP 
59500 at concentrations of four times the minimal bactericidal con- 
centration (MBC) for S. aureus (1.7 pg/ml), and S. epidermidis (2 
pg/ml) for either 6 h or 24 h exposure at 37°C. 
Results: Without antibiotics, adherence of S. aurew to the fi- 
bmnectin-coated catheter surface was 5-times greater than that of 
S. epidermidis (6.0 x 103/cm2 vs 1.2 x 103/cm2). Concentrations 
of 4X MBC of RF' 59500 achieved siguficant reductions in bac- 
terial counts of S. aurew and S. epidermidis, i. e. after 6 h exposure 
by the factors 5 and 300, respectively, and after 24 h by the factor 
2000 for S. aureus, whereas 24 h treatment resulted in the complete 
elhimation of S.  epidermidis. 
Conclusions: Results suggest that RF' 59500 may be a useful 
agent for the treatment of catheter-related staphylococcal infections 
in patients where i. v. catheters cannot be removed/must be left in 
place. The sigdcance of these findmgs should be investigated in 
clinical trials. 
lp11627 QuinupristinlDaIfopristin (Q/D) Combined with 
Doxycycline (0) against Vancomycin-Resistant 
Enterncoccus faeciurn (VREF) in Kill Curve 
Studies and in an In Vitro Infection Model with 
Simulated Endocardial Vegetations (SEVs) 
J. Aeschlimann, M. Zervoe, M. Rybalc. The Anti-Injctiue Research 
Luborafory, Wayne State University and Detroit Receiving Hospital, 
Defroit, MI, U S A  
Objectives: P r e b a r y  stumes indicate that the combination of 
Q/D and D (Q/D + D) is additive or synergistic against VREE 
We evaluated the activity of Q/D, D, and Q/D + D in time-kill 
curve (KC) studies against three clinical isolates of VREE We also 
performed a pilot evaluation of Q/D + D against VREF in an in 
vim simulated endocardd vegetation (SEW model. 
Methods: Microddution MICs and MBCs for Q/D and D were 
performed using standard methods. KCs were performed over 24 
hours using expected peak serum concentrations of Q/D (6 pg/ml) 
and D (4 pg/ml). For the SEV models, SEVs were infected with 
-lo9 CFU/g of VREF 12366. Q/D and D were dosed to simulate 
regimens of 7.5 mg/kg q 8 hours and 200 mg q 24 hours, respec- 
tively. SEV bacterial density was determined at time = 0, 8, 24, 48, 
72, and 96 hours. 
VREF MIC/MBC, @ g / d  KC data (d d u a  arc logio CFU/ml) 
Isolate 
Q/D D SI+ Q/D @ 24 h D @ 24 h Q/D+D @ 24 h GC 
12.311 0.5/2.0 0.125/8 5.7 2.0- 4.9 2.0* 8.6 
13,557 L o b 6 4  8.0/>64 5.9 3.7 7.9 2.0* 8.6 
12,366 0.25/16 0.25/16 5.7 4.2 5.5 3.7 8.6 
Swing  inoculum; ' & n i t  of detecnon 
Results: 
Q/D MICs were similar for a l l  3 strains, but there was substantial 
variation in MBCs. Reduction in log&N/mi for Q/D alone was 
associated with the Q/D MBC. Q/D + D was addtive against the 
VREF with increased MBCs, even when the isolate was resistant to 
D (VREF 13557). Reductions in bacterial inocula at 96 hours in 
the SEV model-(expressed as A logloCFU/g) were: -1.0 for Q/D, 
-1.0 for D, -2.5 for Q/D + D, and +1.6 for GC. 
Conclusions: In KCs, the activity of Q/D and adduivity of Q/D 
+ D against VREF were associated with the Q/D MBC. In the SEV 
model, Q/D + D was additive against a strain of VREF with a low 
Q/D MBC. Further study of Q/D + D against VREF with elevated 
Q/D MBCs in the SEV model is warranted to better characterize 
the activity of this combination. 
I P1163 1 In Vim Activity of Quinupristin/Dalfopristin 
(RP 59500) on Enterncoccus faecais Clinical 
Isolates 
E.J. Giamarellos-Bourboulis, €! Grecka, M. Grammatikou, 
H. Giamarellou. 1" Dept. Prop. Med., Athens Med. S h w l ,  Greece 
Objective: To evaluate the in vitro activity of W 59500, a 3:7 
mixture of the semisynthetic derivates of pristinamycin IA and IIA, 
on E.Jaecalis. 
Methods: 78 isolates from 8 Merent hospitals were tested. MICs 
to RP 59500, ampicillin, amoxycillin + cladanate and vancomycin 
were determined by a microdilution technique with a 5 x lo5 
&/ml overnight inoculum and MBCs by plating the content of 
all clear wells onto blood agar (99.9% of killing). 
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Results: Results were as follows: 
RmgeofMlCr MIC50 MICw MBCso MBCpo %I&bited 
Ampicihn (qb 0.25->8 0 5  >8 4 >8 87.2 
Amox. Clae (8/4) 50.5/0.25>8/4 <0.5/0.25 4/2 412 >8/4 87.2 
RP 59500 (2) 50.015->32 8 >32 >32 >32 30.8 
Vancomycin (4) 50.25-1 0.5 1 2 8 100.0 
a: &g/ml, b: breakpoint 
Conclusions: RP 59500, even though less active than a m p i c b  
on E .  fnecalis, retains an in vitro potential on 31% of isolates which 
raises future pmspectives for its application in antimicrobial combi- 
nations against these isolates. 
I PI164 I Bactericidal Activity of Clarithromycin (CL) and 
Azithromycin (AZ) Against Streptococcus 
pneumoniae (Sp) Strains in Argentina 
J.M. Casellas, M. Gilardoni, G. Torm;, S .  Merino, M.E. Ordunae, 
S. Ivanovic. Centro de Estudios en Antimicrobianos, San Fernando, 
Argentinn 
Resistance to macrolides and azalides among Sp has shown to be low 
in South American surveillances. MICs of CL, AZ and p e n i d h  
(PE) were determined against 200 consecutive Sp isolates obtained 
b m  blood, CSF OMA efussion, sputum, BAL, pleural fluid and 
maxihr sinus. PE susceptibility (PS) (10.06 mg/L) was found in 
152 isolates; intermemate resistance (PI) (0.1-1 mg/L) in 39 (19.5%) 
and PE resistance (PR) (>1  mg/L) in 9 isolates (4.5%). Only 2 CL 
resistant (1 PS and 1 PR) (1%) and 7 AZ resistant strains (5 PI and 
2 PR) (3.5%) were found. MIC50 for CL and AZ were 0.016 and 
0.19 mg/L and MIC90 were 0.016 and 0.5 mg/L respectively. Time 
killing curves were performed for 6 Sp strains with PE MIC's of 
< 0.016; 0.06; 0.25; 0.5; 1 and 2 mg/L against CL and AZ at 2 
MIC and 4 MIC. Survivors were determined at 0, 2, 4, 8 and 24 h. 
With CL complete &g was observed at both concentrations at 2 
h of incubation for 3 shains and at 4 h for 2 strain (PI and CL 0.06 
mg/L). With AZ killing was observed at 4 h for 4 shains and only 
at 8 h for other 2 (PI and AZ 0.25 mg/L). R e p &  was observed 
at 24 h. In 2 strains TKC performed at pH 6.0 showed very slow 
killing both for CLA and AZ but was not observed with CL. 
Conclusions: 1) CL and AZ mantain good activity against Sp 
in the South Cone of America even with PI and PR isolates; 2) 
CL showed bgher bacteriostatic and bactericidal activity than AZ 
against Sp isolates. 
I PI165 I In vitm Activity of Aziihmmycin Against 
Haemophilus influenzae (HI) Isolates Collected 
From 12 Countries 
D.J. Hoban, J.A. Karlowsky, A.M. Kabani, G.G. Zhanel. Clinical 
Microbioloa, Health Snences Centre, Winnipeg, Canada 
Objectives: To compare the in vitro activities of azithromycin (A), 
erythromycin (E), clarithromycin (C) and roxithromycin (R) against 
653 HI isolates collected fkom 12 countries. 
Methods: During 1995-96 as part of a multicentre study 26 hos- 
pital labs b m  12 countries on 3 contments collected 653 HI isolates 
from clinical specimens (>90% respiratory tract). Organisms were 
Anubiouc Rmge MIC5o MlCgo 
A 0.068 1 2 
E 0.12516 4 8 
C 0.25-32 8 16 
R 0.532 8 16 
identified to species level using current lab practices and submit- 
ted for reference minimum inhibitory concentration (MIC) testing. 
MICs were determined in Haemophilus test me&um udltvng a broth 
microdilution technique specified by the NCCLS (1995). 
Results: The MICso and MIC90 values (Wg/ml) are shown in the 
table. 
Conclusions: Of the macrolide antimicrobials examined 
azithromycin demonstrated the highest oved  in vitro activity against 
HI. 
1 PI166 I Streptococcus Pyogenes Isolates Susceptibility 
R. Colodner W Sakran 2, Y. Keness ' , R. Raz '. ' The Microbiolon 
Lboratory, Afula, Israel, The Infectious Diseuses Unif, Haemek Medical 
Center, A@, hml 
Erythromycin is considered the drug of choice in the treatment of 
streptococcal pharyngitis in patients allergic to penicdh. Suscep- 
tibility tests to penicillin and erythromycin are not performed rou- 
tinely because S .  pyogenes is lughly sensitive to both drugs. However, 
in recent years several publications, especdy in Fdand and Italy, 
showed high resistance rates of S .  pyogenes isolate to erythromycin 
and other new macrolides. In order to evaluate the situation in our 
country, we checked the MIC of isolates &om patients with tonsil- 
litis during 1996. E-test results showed a MIC-50 of 0.23, 0.13 and 
0.47 y g / d  for erythromycin, chlarithromycin and roxithromycin, 
respectively. In the same order, MIC-90 was 0.37, 0.23 and 0.78 
F g / d .  Only two isolates (2.1%) were partially or fully resistant to 
the three antibiotics. From these results we can conclude that em- 
piric therapy with micmlides in our region is sti l l  viable and can be 
recommended in S .  pyogenes tomilhtis of penicillin allergic patients. 
However, routine susceptibility testing must be considered in order 
to detect early appearance of resistance. 
to Three Macrolides in the Jerreel Valley 
I PI1 67 I In vitm Activity of HMR 3004 (RU 64004) 
against 512 Strains of Anaerobic Bacteria 
H.M. Wexler, E. Molitoris, S.M. Finegold. VAMC and U C L A  Los 
Angeles, C4, USA 
The in vitro activity of HMR 3004 (RU 64004) was compared 
to azithromycin (AZ), clarithromycin (CL), erythromycin (ER) 
and roxithromycin (RO). Anaerobes (512) were tested using the 
NCCLS-approved Wadsworth brucella laked blood agar dilution 
method. Breakpoints for the inclusion of strains into the suscep- 
tible category were 4 u g / d  for all agents. Organisms tested in- 
cluded Bacteroides jagilis (77), other B. jagilis group species (129), 
Campylobactergrm'lis (13), Bacteroides species (13). Fwobartm'um nuclea- 
hrm (27). E mortiiemm/varium (16). other Fusobacterium (l l) ,  Bilophila 
wadswrfhia (27), Peptostreptococcus (35), Porphytumonas sp. (14), Pre- 
votella sp. (42), Sutterelh wadsorthensis (16), Closhidium d&le (16). 
other Closhidium species (40) and gram-positive non-sporeforming 
rods (32). RU 64004 inhibited 78% of B.jagilis and 69% of B.jagilis 
groups species, respectively. Ninety-three percent of other Bacteroides 
were inhibited, compared to 80% for AZ, 87% for ER, and 93% 
for CL and RO. RU 64004 and AZ inhibited all Porphyromom 
species, compared to 9 3 4 %  for the other agents. RU 64004 i h b -  
ited 98% of Preuotella compared to 91%, 93%, 93% and 95% for ER, 
AZ, RO and CL, respectively. Activity against Bilophila wadsworthia 
(96%) was excellent compared to poor or no activity for the other 
macrolides. All agents inhibited 100% of Closm'dium pnfnngem and 
-50% of C. d&Ze and C. ramosum. None of the agents had activ- 
ity against the Fwobactm'um mortiferum/varium group. Approximately 
90% of non-sporeforming gram-positive rods were inhibited by all 
288 Journal of Clinical Microbiology and Infection, Volume 3 Supplement 2 
of the agents. Overall, RU 64004 had the best activity against anaer- 
obes, inhibiting 77% compared to AZ (46%), CL (73%), ER (47%) 
and RO (46%). 
I P1168 I Activity of Liposomal Antibiotics against 
Pseudomonas aeruginosa Attached to the 
Human Dennis 
E.A. T&y, M. Antos-Bielska, J. Grzybowslu. Mil. Inst. ofHygiene 
and Epidemiology, Warsaw, Poland 
Objectives: To compare action of liposomal &cin (LipAmi), 
ciprofloxacin (LipCipm), and polymyxin B GpPolB) against 72 h 
biofilm of P amgimsa growing on the sections of the human dermis. 
Methods: Dermis was prepared as follows: the skin was dim- 
fected in 85% glycerol and incubated in 1M NaCl for removal of 
epidermis. Cationic liposomes were produced from egg lecithin, 
stearylamine and cholesterol. Encapsulation efficiency was 3% for 
amikacin, 50% for ciprofloxacin, and 100% for polymyxin B. €? m g -  
inosa biofilms were formed by incubation of dermis sections for 72 h 
in the suspension (lo5 CFU/ml) of eight strains isolated from burn 
wounds. Skin sections were shaked for 1 h in liposomal suspensions. 
The residual viable cells were removed by sonication and plated on 
Mueller-Hinton agar. 
R e d -  The following concentrations of antibiotics were re- 
leased from liposomes during 1 h incubation: amikacin 8 ug/ml, 
ciprofloxacin 16 ug/ml, polymyxin B 2.5 ug/ml. After treatment 
with liposomes the means percent of viable cells attached to skin 
dermis were 45.4% for LipAmi, 17.4% for LipCipro, and 19.3% for 
LipPoIB compared to control samples. A correlation between the 
number of deattached cells and MIC values was observed only for 
LipCipm. For that formulation an almost complete (>99.5%) eradi- 
cation of attached cells was noticed for four strains. 
Conclusions: Cleansing of the colonized human dermis with 
LipCipro or LipPoIB seems to increase the &cacy at the removal of 
attached bacteria. 
1-1 Antibacterial Effects of Refined Products of 
Metabolism (Metabolite) of Bifidobacterium 
bitidum 
D. Nikolit ', G. Dakit ', Lj. Dimitrijevit ', D. Prekajski ', 
M. Svabit-Vlahovit *. lInstitute oflmmunology and Krology, Torlak, 
Belgrade, Yugoslavia, 21nstitute ofMinobiology and Zmmumlon, School of 
Medin'ne, University $Belgrade, Yugoslavia 
With a specific stimulation in 5% glucose, and by addmg microele- 
ments, refined metabolite of Bijidobacten'um bijidum were obtained. 
By immunochemical analysis we established that refined metabolite 
products were proteins of molecular weight less than 10 kd, and 
that they were biologically active. Antibacterial activity of refined 
metabolite products were tested by pouring in apertures, with the 
agar ditfuuon method. Examinations were performed on strains of 
S. a u m .  E. faecalis, Salmonella typhi, E .  coli, ShigellapeXneri, obtained 
from patients material and S. aureus ATCC 29213. On Muller Hin- 
ton agar apertures of 16 mm diameter were perforated, inoculated 
with bacterial suspension following an antibiogmn standard, then 1 
ml of active substance was poured in halls. After 24 hours of incu- 
bation the biggest diameter of the inhibition zone of growth was 
44 mm for S.  aureus and the smallest was 36 mm for Salmonella 
typhi. Control plates poured with medium adjusted pH did not 
give any sipficant zones of inhibition growth. Refined products 
of metabohm of Bijidobarterium bijidum were harmless which was 
confirmed with a biological test of harmlessness. 
I P1170 I In Vitm Activity of Trimethoprim (TMP) and 
Epiroprim (EPI) Alone and in Combination with 
Sulfamethoxazole (SSS) against Clinical 
Bacterial Isolates 
C.S. Boye ' , E. Macondo ' , 0. Kaid ' , L. Haller ', S. Mboup ' . 
'Bacthiologie le Dantec, Dakar, Sknkgal, 'Fondation Roche Abidjan Cite 
d'hire  , Sinkgal 
Objectives: To compare the efficiency of Epiroprim and Trimetho- 
prim alone and in combination with the Sulfamethoxazole on non- 
fastidious aerobic strains. 
Methods: 116 strains were tested by two antibiotics: EPI and 
TMP alone and in combination with the SSS by the agar dilution 
method. 
Results: S. aureus: EPI alone, the ME50 was 0.667 pg/ml and 
the MIC90 1.933 pg/ml. EPI in combination the MIC50 was 
0.0286/0.5434, the MIC90 of 0.475/9.025. TMP alone, the MIC50 
was 5.333 pg/ml and the ME90  >256 pg/ml. TMP in combi- 
nation: we obtained a MIC5O of 0.0625/1.1875 and a MIC90 of 
0.425/8.075. 
Gram negative bacilli: we distinguished 2 groups: the first in- 
cluding Entembacter, Salmonella and Shigella in which EPI alone 
gave a MIC50 t l  pg/ml. In combination the result was s&.
With TMP alone the MIC50 and the MIC90 were 2256 pg/ml. 
In combination Salmonella and Shgella gave MIC50 and MIC90 
50.09/1.71. The second group including Klebsiella, E .  coli, Ps a m g -  
inosa and P mirabilis with EPI alone showed a MIC90 r256 pg/ml. 
In combination the MIC50 decreased from 0.5/9.5 to 14/266 with 
a MIC90 >16/304. TMP alone, showed a MIC90 2256 kg/ml. In 
combination, the MIC5O decreased for Klebsiella and E .  coli. 
Conclusions: The results have shown that EPI is better than 
TMP among S. a u m  strains. Among Gram-negative bacilli, EPI 
is more efficient in the first group and TMP in the second. In 
combination, we observed the same result except for Salmonella and 
Shigella where TMP/SSS was better than EPVSSS. 
In Vim Activity of New Oxazolidinones, 
Eperezolid (U-100592) and Linezolid (U-100766). 
against Staphylococci and Enterococci 
R. Leclercq. H6pital Hmri Mondor-Uniwrsid Paris XU, Crhteil, France 
Objectives: To test the in vim activity of new oxazolidinones, 
eperezolid (U100766) and linezolid (U100592), against clinical iso- 
lates of staphylococci and entemcocci, including multidrug-resistant 
Strains. 
Methods: 113 clinical isolates of S. a u m ,  including 52 methi- 
cillin-resistant and 11 pristinamycin-resistant strains, 102 coagulase 
negative staphylococci (62 Staphylococcus epidmidis and 40 other co- 
agulase-negative staphylococci) and 102 enterococci including 32 
strains intermedrate or resistant to vancomycin were studied. MICs 
of vancomycin, eperezolid and linezolid against all strains, and of 
ampicillin and gentamicin against enterococci were determined by 
the agar-dilution technique. 
Results: 1/ MICs of eperezolid and hezolid ranged from 0.25 
to 2 mg/L against all strains of staphylococci (MICs90 = 2 mg/L), 
regardless of the bacterial species and of whether they are resistant to 
methicillin or pristinamycin. MICs of vancomycin ranged from 0.5 
to 4 mg/L. Linezolid appeared slightly more effective against certains 
s t r a i n s  than eperozolid, although no aerence in the MICs90 of the 
two drugs was found. 
2/ MICs of eperezolid and linezolid ranged from 0.5 to 2 mg/L 
against entemcocci (MICs90 = 2 mg/L), including ampicillin-, van- 
comycin- and/or gentamicin-resistant strains. 
Conclusion: The new oxazolidinones, eperezolid and linezolid, 
Epidemiology and resistance in pneumococci and other Gram-positive cocci 28s 
were active againsc all strains of staphylococci and enterococci be- 
longing to various species, including multi-drug resistant isolates. On 
the basis of these in vitru results, the oxazolidinones could be alterna- 
tives to vancomycin or beta-lactams against Gram-positive organisms 
in particular when the strains are multiply resistant to antibiotics. 
[ PI172 I Susceptibility of Various Gram-Positive 
Bacteria to Eperezolid (U-100592) and Linezolid 
(U-100766) 
C.G. Gemmell, M. Ferguson, B. Cosgrove. Depadment of 
Bacterioloa, GIasgoru Royal Infirmary University N H S  Tnrst, Glasgow, 
Scotland 
Objectives: To assess the susceptibility of a range of clinical isolates 
of gram-positive cocci to the oxazolidinones. 
Methods. Staphylococcus epidermidis (100 strains) ,  Staphylococcus QU- 
reus (98 strains), E~zterococcus~aecalis (50 strains) and Streptocm pneu- 
moniae (113 strains) were tested for their susceptibility to Epere- 
zolid (EZD) and Linezolid (LZD) using a s t a n u s e d  agar di- 
lution assay. Included in the collection of strains tested were 83 
MRSE, 69 MRSA, 38 penicillin-resistant pneumococci and 6 van- 
comycin-resistant enterococci. 
Results: Amongst the s t r a i n s  of Staphylococcus epidermidis 99/100 
were sensitive to 50.5 mgA EZD and 96/100 to LZD. Of29 MSSA, 
28 were susceptible to 50.5 mg/l EZD and only 5/29 were suscep 
tible to the same concenttation of LZD; 28/29 were susceptible to 
1 mgA. By comparison 64/69 s t r a i n s  of MRSA were sensitive to 1 
mg/l LZD in comparison to only 44/69 with EZD. All enterococci 
were sensitive to 50.5 mg/l of either agent. Susceptibility of the 
pneumococci to each agent Hered  slightly - 111/113 were suscep- 
tible to 0.25 mgA EZD whereas only 95/113 were susceptible to 
this concentration of LZD. All were susceptible to 0.5 mg/l of either 
Conclusions: Both oxazohdmones exhibited good in viho activ- 
ity against a range of clinical isolates of gram-positive cocci, some 
of whch were resistant to other antibiotics. Concomitant drug re- 
sistance did not appear to dec t  their susceptibility to the oxazolidi- 
nones. LZD is now undergoing phase I1 h c a l  trials. 
drug. 
I PI173 I Comparative In Vim Activity of Eperezolid 
(EZD) (U100592) and Linezolid (LZD) (U100766) 
against S. aureus (SA), S. epidennidis (SE) and 
S. pneumoniae (SP) 
M.D. Kitzis, J.E Acar, EW. Goldstein. Fondation H6pital Saint-Joseph, 
Paris, France 
The in vim activity of EZD and LZD was studied against 95 SA (62 
MRSA), 92 SE (25 MRSE) and 95 SP (48 peni S = 5 0.06 mg/l, 
16 peni I = 20,125-51 and 31 peni R = 2 2  mg/l). The MICs of 
EZD and LZD were determined by agar dilution in Mueller-Hinton 
agar (+5% horse blood for SP) in comparison to vancomycin (van), 
teicoplanin (tec), oxacillin against SA and SE, and to van, tec, peni- 
cillin, amoxicillin, cehroxime, cefotaxime and erythromycin against 
SF’. The MIC range and 50% were as follows: 
EZD U D  VAN TEC 
MSSA 0.5-4 (2) 
MRSA 1-4 (1) 
MSSE 0.5-4 (1) 
MRSE 1-4 (1) 
SP pem S 0.5-2 (I) 
SP peni I 0.5-2 (1) 
SP D C N  R 0.52 (1) 
1-4 (2) 0 . 5 2  (1) 0.5-4 (2) 
0.54 (1) 0.5-2 (1) 0 .54  (2) 
0.5-2 (1) 1-2 (2) 0.25-16 (4) 
1-2 (1) 1-4 (2) 0.516 (2) 
1-4 (2) 0.1251 (0.25) 0.03-0.125 (0.06) 
1-2 (2) 0.254.5 (0.25) 0.03-0.125 (0.06) 
0 . 5 2  (1) 0.12545 (0.25) 0.03-0.25 (0.06) 
The MICs of EZD and LZD against SA and SE were lower 
than tec and similar to van. EZD and LZD are less active than van 
and tec against SP but with a MIC 90% of 1-2 mg/l, a clinicaly 
achievable level. The activity of EZD and LZD were similar on SA, 
SE and SP susceptible or resistant to ,!?-lactams or other antibiotics. 
With the increased fiequency of multiple antibiotic-resistant bacteria 
new compounds which don’t exhibit cross-resistance to available 
antibiotics are highly desirable. These data suggest that EZD and 
LZD are promising compounds and warrant further in vim and 
clinical studies. 
Epidemiology and resistance in pneumococci 
and other Gram-positive cocci 
[%I Nosocomial Outbreak of Cefotaxime Resistant 
Streptococcus pneumoniae Infections in a 
Geriatric Ward 
C. Vael’, M. Ieven ’, E Tenover ’, H. Goossens ’. ’J. Pafin 
Hospital, Antwetp, Belgium, University Hospital, Antwerp, Belgium, 
3Centersfor Disence Conhol and Prevention, Atlanta, USA 
Objectives: To describe an outbreak of p e n i c h  and cefotaxime 
resistant Streptocorn pneumoniae ( S p )  mfections and to evaluate the 
E-test as compared to the microbroth dilution (MBD) method in 
the detection of this type of resistance. 
Methods: During 7 weeks 6om december ’95 until january ’96 
8 Spn strains were isolated 6nm 8 geriatric patients (median age 79, 
range 69-85 years). Penicillin and cefotaxime MIC determinations 
were performed by E-test (AB Biodisk, Sweden) and confirmed by 
NCCLS MBD. Patient medical records were reviewed. Spn s t r a i n s  
were serotyped and analysed by PFGE. 
Results: All strains were penicillin and cefotaxime resistant (MIC 
= 2 ,ug/ml) by MDB method. Penicillin and cefotaxime E-test MICs 
were equal or one log2 dilution lower as compared to MBD. All 
strains were identical by semtyping (type 14). Clinical pneumonia 
developed in all patients with 25% (2/8) mortality. Most (618) pa- 
tients suffered h m  COPD. Seven out of eight patients were ad- 
mitted to the same geriatric ward. Previous beta-lactam therapy was 
observed in 7/8 patients. Median duration of hospitalisation before 
infection was 31 days (range 13-78). In the 3 month period pre- 
ceeding and during the outbreak 54 other Spn s h a h s  were isolated 
with cefotaxime MICs 5 0.5 pg/ml. 
Conclusion: Although previously no cefotaxime resistant Spn 
were detected in Belgium, we observed an outbreak in a geriatric 
ward in association with typical risk factors for selection of resis- 
tance. E-test is a reliable method to detect penicillin and cefotaxime 
resistance in Spn. 
I P1175 I Antimicrobial Resistance and Serotype 
Distribution of Streptococcus pneumoniae 
Isolates in a Turkish Hospital 
S. Kocagoz, D. Giir, S. Unal. Department OfInfeCtious Disease, 
Hacettepe University Medical School, Ankara, Turkey 
Objectives: Clinical isolates of Sheptococcus pneumoniae with de- 
creased penicillin sensitivity and multiple antibiotic resistance have 
been reported worldwide. A study was performed relating the 
serotypes and antibiotic susceptibdities of S. pneumoniae that were 
isolated 6nm adult age group of patients who were admitted to 
Hacettepe University Teaching Hospital between 1992 and 1995. 
